Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

How To Get A Bill Through Congress: Pediatric Cancer Treatment Advocate Scores 2 Wins, 1 Loss

Jan 05 2023

• By Brenda Sandburg

pediatric cancer — Bill authorizing FDA to require pediatric studies of investigational cancer drug combinations is left out of omnibus funding package • Source: Shutterstock

Related Content

Priority Review Voucher Programs Poised For US Legislative Attention In 2020

Feb 18 2020

Pediatric Cancer Study Requirements Added To FDA User Fee Bill

Jul 12 2017

US FDA’s Pediatric Cancer Targets List Spurs Questions On Breadth, Prioritization

Apr 27 2018

Pediatric Cancer Studies: US FDA Promises Flexible Approach On Requirements

Feb 23 2018

US FDA Could Require Pediatric Cancer Drug Combo Studies Under Amended User Fee Bill

May 19 2022

US FDA User Fee Legislation: Is Sen. Burr’s ‘Clean’ Bill A Lifeline – Or A Wrench In The Works?

Jul 15 2022

Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, FDA Says

Mar 03 2016

Additional Topics

United States Legislation Pediatrics Clinical Trials FDA Lobbying Policy Politics Pink Sheet Perspectives Cancer BioPharmaceutical

More from Pink Sheet Perspectives

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window